WO2008119146A3 - Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd - Google Patents

Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd Download PDF

Info

Publication number
WO2008119146A3
WO2008119146A3 PCT/BR2008/000093 BR2008000093W WO2008119146A3 WO 2008119146 A3 WO2008119146 A3 WO 2008119146A3 BR 2008000093 W BR2008000093 W BR 2008000093W WO 2008119146 A3 WO2008119146 A3 WO 2008119146A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphoethanolamine
day
omega
bronchial asthma
combi
Prior art date
Application number
PCT/BR2008/000093
Other languages
French (fr)
Other versions
WO2008119146A8 (en
WO2008119146A2 (en
Original Assignee
Dair Bicudo Piai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dair Bicudo Piai filed Critical Dair Bicudo Piai
Priority to PCT/BR2008/000093 priority Critical patent/WO2008119146A2/en
Publication of WO2008119146A2 publication Critical patent/WO2008119146A2/en
Publication of WO2008119146A3 publication Critical patent/WO2008119146A3/en
Publication of WO2008119146A8 publication Critical patent/WO2008119146A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The object of the invention is a composition for the treatment of bronchial asthma and chronic obstructive pulmonary disease, characterized in that the composition comprises phosphoethanolamine and Omega-3 folly acids in pre-established proportions. The preferred dose is 400 to 1200 mg/day, more specifically 800 mg/day for the phosphoethanolamine and 500 to 3200 mg/day, more specifically 1000 mg/day for the cicosapentaenoic acid 'EPA' and 350 to 2000 mg/day, more specifically 750 mg/day for the cocosahexaenoic acid 'DHA'.
PCT/BR2008/000093 2007-03-29 2008-03-31 Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd WO2008119146A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BR2008/000093 WO2008119146A2 (en) 2007-03-29 2008-03-31 Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0701374-4 2007-03-29
PCT/BR2008/000093 WO2008119146A2 (en) 2007-03-29 2008-03-31 Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd

Publications (3)

Publication Number Publication Date
WO2008119146A2 WO2008119146A2 (en) 2008-10-09
WO2008119146A3 true WO2008119146A3 (en) 2008-12-18
WO2008119146A8 WO2008119146A8 (en) 2010-02-18

Family

ID=41678990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2008/000093 WO2008119146A2 (en) 2007-03-29 2008-03-31 Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd

Country Status (1)

Country Link
WO (1) WO2008119146A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016008247A2 (en) * 2016-04-13 2017-10-17 Acolli S.A. FOOD SUPPLEMENT BASED ON 2-AMINOETHANOL DIHYDROGENOPHOSPHATE AND SYNTHESIS PROCESS
WO2024073678A2 (en) * 2022-09-30 2024-04-04 Omega Therapeutics, Inc. Phospholipids containing a heterocycle ring having a tertiary amine or amide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021912A1 (en) * 1992-04-28 1993-11-11 Fresenius Ag Use of an emulsion containing omega-3 fatty acids to produce a medicament to be parenterally administered for treating inflammatory diseases
WO2004064716A2 (en) * 2003-01-24 2004-08-05 Pabay Investments Limited Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders
US20050080052A1 (en) * 1998-11-26 2005-04-14 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2005089744A2 (en) * 2004-03-17 2005-09-29 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2007026071A1 (en) * 2005-09-01 2007-03-08 Pieroni Gerard Use of dha in the form of phospholipids for the preparation of a composition that is intended for the treatment of respiratory failure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021912A1 (en) * 1992-04-28 1993-11-11 Fresenius Ag Use of an emulsion containing omega-3 fatty acids to produce a medicament to be parenterally administered for treating inflammatory diseases
US20050080052A1 (en) * 1998-11-26 2005-04-14 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2004064716A2 (en) * 2003-01-24 2004-08-05 Pabay Investments Limited Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders
WO2005089744A2 (en) * 2004-03-17 2005-09-29 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2007026071A1 (en) * 2005-09-01 2007-03-08 Pieroni Gerard Use of dha in the form of phospholipids for the preparation of a composition that is intended for the treatment of respiratory failure

Also Published As

Publication number Publication date
WO2008119146A8 (en) 2010-02-18
WO2008119146A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
JP2010195825A5 (en)
JP2010259437A5 (en)
JP2010516662A5 (en)
IL243178A0 (en) Double-stranded ribonucleic acids (dsrna) for inhibiting expression of transthyretin (ttr), pharmaceutical compositions comprising them and use thereof in the treatment of disorders mediated by ttr expression
WO2006014353A3 (en) Glycogen or polysaccharide storage disease treatment method
EP2749280A3 (en) Combination of glycopyrronium and formoterol
HK1214762A1 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2014074552A3 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
WO2008119457A3 (en) Lactam-substituted dicarboxylic acids and use thereof
JP2013005786A5 (en)
RS63398B1 (en) Inhalation composition containing aclidinium for treatment of chronic obstructive pulmonary disease
WO2007100561A3 (en) Use of dha and ara in the preparation of a composition for preventing or treating obesity
CO6361899A2 (en) INHALABLE PARTICLES THAT INCLUDE TIOTROPIO
MY167387A (en) Orally administered adsorbent
WO2009010810A3 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
WO2009140383A3 (en) Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics
WO2009099998A3 (en) Therapeutic treatment for lung conditions
WO2008119146A8 (en) Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
EP2120935A4 (en) Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733496

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: PI 0701374-4

Country of ref document: BR

Date of ref document: 20090925

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

122 Ep: pct application non-entry in european phase

Ref document number: 08733496

Country of ref document: EP

Kind code of ref document: A2